Incretin Effect in Lean and Obese Subjects

Completed

• Conditions: Incretin Effect; Insulin Resistance; Type 2 Diabetes
• Interventions: Other: Oral glucose tolerance test (OGTT); Other: Isoglycemic intravenous glucose infusion

• Registration Number: NCT00803296
• Lead Sponsor: University Hospital, Gentofte, Copenhagen

Brief Summary

The incretin effect is markedly reduced in patients with type 2 diabetes. Data support the notion that this deficiency is a consequence of the diabetic state. However, the impact of insulin resistance on the incretin effect in obese individuals who uphold a normal glucose tolerance (NGT) despite their insulin resistant state remains to be elucidated. The primary aim of the present study is to evaluate the separate impact of one of the cornerstones of type 2 diabetic pathophysiology, namely insulin resistance, on the incretin effect in lean and obese patients with type 2 diabetes and in two matched normal-glucose tolerant groups of healthy control subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01
• Primary Completion: 2008-01
• Study Completion: 2008-06
• Status Verified: 2008-12
• Study First Submitted: 2008-12-04
• Study First Submitted QC: 2008-12-04
• Study First Posted: 2008-12-05
• Last Update Submitted: 2010-01-12
• Last Update Posted: 2010-01-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 32

Inclusion Criteria

• Diagnosed with type 2 diabetes for at least 3 months
• Normal blood hemoglobin
• Informed consent

Exclusion Criteria

• Liver disease
• Diabetic nephropathy
• Treatment with medication that can not be stopped for 12 hours

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Obese patients with type 2 diabetes	Isoglycemic intravenous glucose infusion	Patients with type 2 diabetes and BMI\>33
Obese subjects with normal glucose tolerance	Oral glucose tolerance test (OGTT)	Subjects with normal glucose tolerance and BMI\>33
Obese subjects with normal glucose tolerance	Isoglycemic intravenous glucose infusion	Subjects with normal glucose tolerance and BMI\>33
Lean subjects with type 2 diabetes	Oral glucose tolerance test (OGTT)	Patients with type 2 diabetes and BM\<25
Lean subjects with normal glucose tolerance	Isoglycemic intravenous glucose infusion	Subjects with normal glucose tolerance and BM\<25
Obese patients with type 2 diabetes	Oral glucose tolerance test (OGTT)	Patients with type 2 diabetes and BMI\>33
Lean subjects with normal glucose tolerance	Oral glucose tolerance test (OGTT)	Subjects with normal glucose tolerance and BM\<25
Lean subjects with type 2 diabetes	Isoglycemic intravenous glucose infusion	Patients with type 2 diabetes and BM\<25

Primary Outcome Measures

Name	Time	Method
Incretin effect	2 days

Secondary Outcome Measures

Name	Time	Method
Insulin resistance	2 days

Trial Locations

Locations (1)

Gentofte Hospital, University of Copenhagen; 🇩🇰 Hellerup, Copenhagen, Denmark